After NACT, patients who presented with cN1 disease should still receive ALND if residual disease found in LNs, but if they have pCR, their survival=cN0 pts’. Some pearls from @DrLolaFayanju on surgical management of breast cancer @DukeCancer review. #bcsm #DCR2019
Duke Cancer Network
@DukeCancerNETWK
The Duke Cancer Network has expertise in building value-based programs that define best practices and enhance quality to best serve the needs of your community.
44 Following 319 Followers 198 Posts
Latest posts 5
Dr. Blitzblau also notes there is accumulation evidence for once weekly and one week courses of radiation therapy for breast cancer as well as more data on safety of hypofractionated nodal treatment #DCR2019
...BUT, Dr. Blitzblau also notes that other schedules are available for individual pts - elderly, limited transportation, etc #DCR2019
Dr Blitzblau @ #DCR2019: ASTRO 2018 Consensus statement of HF-WBRT expanded indications: PREFERRED dose fractionation scheme is HFWBI to dose of 4000 cGY in 15 fractions or 4250 cGY in 16 fractions for women w/ invasive br ca receiving WBI w/wo inclusion of low axilla....
Dr Sarah Sammons notes top recent wins in breast cancer: 4. OS benefit for pre/perimenopausal women with ribociclib + endocrine Rx in 1st line ER+/HER2- advanced disease #DCR2019